

CHAPTER 267
HB 656 - FINAL VERSION

05/30/2019 2389s

2019 SESSION

19-0799
01/03

HOUSE BILL **656**

AN ACT establishing a committee to study the impact of financial initiatives for commercially insured members by drug manufacturers on prescription drug prices and health insurance premiums.

SPONSORS: Rep. Butler, Carr. 7; Rep. Marsh, Carr. 8; Rep. Knirk, Carr. 3; Rep. Hennessey, Graf. 1; Sen. Bradley, Dist 3; Sen. Sherman, Dist 24

COMMITTEE: Commerce and Consumer Affairs

AMENDED ANALYSIS

This bill establishes a committee to study the impact of financial initiatives for commercially insured members by drug manufacturers on prescription drug prices and health insurance premiums.

Explanation: Matter added to current law appears in ***bold italics***.
Matter removed from current law appears ~~[in brackets and struckthrough.]~~
Matter which is either (a) all new or (b) repealed and reenacted appears in regular type.

CHAPTER 267
HB 656 - FINAL VERSION

05/30/2019 2389s

19-0799
01/03

STATE OF NEW HAMPSHIRE

In the Year of Our Lord Two Thousand Nineteen

AN ACT establishing a committee to study the impact of financial initiatives for commercially insured members by drug manufacturers on prescription drug prices and health insurance premiums.

Be it Enacted by the Senate and House of Representatives in General Court convened:

1 267:1 Committee Established. There is established a committee to study the impact of financial
2 initiatives for commercially insured members by drug manufacturers on prescription drug prices and
3 health insurance premiums.

4 267:2 Membership and Compensation.

5 I. The members of the committee shall be as follows:

6 (a) Four members of the house of representatives, appointed by the speaker of the house
7 of representatives.

8 (b) One member of the senate, appointed by the president of the senate.

9 II. Members of the committee shall receive mileage at the legislative rate when attending to
10 the duties of the committee.

11 267:3 Duties.

12 I. The committee shall study how financial initiatives for commercially insured members
13 impact the cost of prescription drug prices and health insurance premiums. The committee's study
14 shall include, but not be limited to:

15 (a) Identifying current financial assistance initiatives for commercially insured members
16 provided by drug manufacturers, both directly and indirectly.

17 (b) How the use of free drug samples, copay coupons, and drug discount cards affects the
18 health plan formularies, use of medications, charges, and payment rates for drugs.

19 (c) How the use of free drug samples, drug copay coupons, and drug discount cards
20 affects medical cost trends and health insurance premiums.

21 (d) How drug manufacturer financial assistance with member cost sharing coordinates
22 within commercial health insurance cost sharing structures, including high deductible health
23 insurance plans.

24 (e) Examining persons, entities, and organizations that benefit from consumer use of
25 drug manufacturer provided financial assistance to commercially insured members.

26 (f) How the use of drug manufacturer provided financial assistance drives market share
27 of certain prescription drugs.

28 (g) Identifying funding provided to patient advocacy groups by drug manufacturers,
29 either directly or indirectly.

CHAPTER 267
HB 656 - FINAL VERSION
- Page 2 -

1 (h) Reviewing legislation from other states and the results of such legislation.

2 (i) How drug manufacturer financial assistance initiatives benefit consumers who cannot
3 otherwise afford their prescription medication.

4 (j) Proposing changes to New Hampshire law to reduce the rising cost of
5 pharmaceuticals.

6 II. The committee shall prioritize studying drug copay coupons with the intent of either
7 proposing an amendment to HB 717-FN of the 2019 regular legislative session or proposing new
8 legislation for the 2020 legislative session.

9 267:4 Chairperson; Quorum. The members of the study committee shall elect a chairperson
10 from among the members. The first meeting of the committee shall be called by the first-named
11 house member. The first meeting of the committee shall be held within 45 days of the effective date
12 of this section. Three members of the committee shall constitute a quorum.

13 267:5 Report. The committee shall make a report with its interim findings by November 1, 2019
14 to the speaker of the house of representatives, the president of the senate, the house clerk, the
15 senate clerk, the governor, and the state library. The interim report shall contain any
16 recommendations for proposed legislation on drug copay coupon programs. The committee shall
17 make a final report with any further recommendations for proposed legislation on or before
18 November 1, 2020 to the speaker of the house of representatives, the president of the senate, the
19 house clerk, the senate clerk, the governor, and the state library.

 267:6 Effective Date. This act shall take effect upon its passage.

Approved: July 19, 2019

Effective Date: July 19, 2019